Androgenic alopecia, also known as seborrheic alopecia, is the most common hair loss disorder in dermatology clinics, mainly characterized by hair follicle miniaturization and progressive hair loss. The etiology and pathogenesis of androgenic alopecia are not clear, but may be related to heredity and androgen metabolism. Currently, minoxidil and finasteride are the only two drugs approved by the U.S. Food and Drug Administration (FDA) for AGA treatment, other treatments include oral minoxidil, hair transplantation, low energy laser therapy (LLLT), platelet-rich plasma (PRP), Chinese medicine microneedles, and combination therapy. With the development of medicine and science, we have ushered in the era of biologics and targeted therapy. In recent years, a variety of signaling pathways for androgenic alopecia have been found, which may provide a basis for targeted therapy for androgenic alopecia.
References
[1]
Rojas-Martínez, A., Martinez-Jacobo, L., Villarreal-Villarreal, C., Ortiz-López, R. and Ocampo-Candiani, J. (2018) Genetic and Molecular Aspects of Androgenetic Alopecia. Indian Journal of Dermatology, Venereology and Leprology, 84, 263-268. https://doi.org/10.4103/ijdvl.ijdvl_262_17
[2]
Liu, Q., Tang, Y., Huang, Y., Wang, J., Yang, K., Zhang, Y., et al. (2022) Insights into Male Androgenetic Alopecia Using Comparative Transcriptome Profiling: Hypoxia-Inducible Factor-1 and Wnt/β-Catenin Signalling Pathways. British Journal of Dermatology, 187, 936-947. https://doi.org/10.1111/bjd.21783
[3]
Vasserot, A.P., Geyfman, M. and Poloso, N.J. (2019) Androgenetic Alopecia: Combing the Hair Follicle Signaling Pathways for New Therapeutic Targets and More Effective Treatment Options. Expert Opinion on Therapeutic Targets, 23, 755-771. https://doi.org/10.1080/14728222.2019.1659779
[4]
Papukashvili, D., Rcheulishvili, N., Liu, C., Xie, F., Tyagi, D., He, Y., et al. (2021) Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy. Cells, 10, Article 2957. https://doi.org/10.3390/cells10112957
[5]
Rodrigues, B.L., Montalvão, S.A.L., Cancela, R.B.B., Silva, F.A.R., Urban, A., Huber, S.C., et al. (2019) Treatment of Male Pattern Alopecia with Platelet-Rich Plasma: A Double-Blind Controlled Study with Analysis of Platelet Number and Growth Factor Levels. Journal of the American Academy of Dermatology, 80, 694-700. https://doi.org/10.1016/j.jaad.2018.09.033
[6]
Roenigk, H.H. (1988) New Topical Agents for Hair Growth. Clinics in Dermatology, 6, 119-121. https://doi.org/10.1016/0738-081x(88)90075-2
[7]
Cai, Y., Jia, Z., Zhang, Y., Kang, B., Chen, C., Liu, W., et al. (2023) Cell-Free Fat Extract Restores Hair Loss: A Novel Therapeutic Strategy for Androgenetic Alopecia. Stem Cell Research & Therapy, 14, Article No. 219. https://doi.org/10.1186/s13287-023-03398-1
[8]
Liu, Q., Shi, X., Zhang, Y., Huang, Y., Yang, K., Tang, Y., et al. (2021) Increased Expression of Zyxin and Its Potential Function in Androgenetic Alopecia. Frontiers in Cell and Developmental Biology, 8, Article 582282. https://doi.org/10.3389/fcell.2020.582282
[9]
Nestor, M.S., Ablon, G., Gade, A., Han, H. and Fischer, D.L. (2021) Treatment Options for Androgenetic Alopecia: Efficacy, Side Effects, Compliance, Financial Considerations, and Ethics. Journal of Cosmetic Dermatology, 20, 3759-3781. https://doi.org/10.1111/jocd.14537
[10]
Huang, J., Ran, Y., Pradhan, S., Yan, W. and Dai, Y. (2019) Investigation on Microecology of Hair Root Fungi in Androgenetic Alopecia Patients. Mycopathologia, 184, 505-515. https://doi.org/10.1007/s11046-019-00345-8
[11]
Mahé, Y.F., Michelet, J., Billoni, N., Jarrousse, F., Buan, B., Commo, S., et al. (2000) Androgenetic Alopecia and Microinflammation. International Journal of Dermatology, 39, 576-584. https://doi.org/10.1046/j.1365-4362.2000.00612.x
[12]
Wang, Q., Yang, K., Lin, J., Liu, Q., Zhu, Y., Li, Z., et al. (2023) Investigation of Oral Finasteride Enhanced Occipital Hair Diameter Index in Different Types of Male Androgenetic Alopecia. Journal of the American Academy of Dermatology, 89, 1292-1294. https://doi.org/10.1016/j.jaad.2023.08.027
[13]
Kim, S., Eum, J., Yang, H. and Jung, H. (2019) Transdermal Finasteride Delivery via Powder-Carrying Microneedles with a Diffusion Enhancer to Treat Androgenetic Alopecia. Journal of Controlled Release, 316, 1-11. https://doi.org/10.1016/j.jconrel.2019.11.002
[14]
Vora, L.K., Donnelly, R.F., Larrañeta, E., González-Vázquez, P., Thakur, R.R.S. and Vavia, P.R. (2017) Novel Bilayer Dissolving Microneedle Arrays with Concentrated PLGA Nano-Microparticles for Targeted Intradermal Delivery: Proof of Concept. Journal of Controlled Release, 265, 93-101. https://doi.org/10.1016/j.jconrel.2017.10.005
[15]
Rosette, C., Rosette, N., Mazzetti, A., Moro, L. and Gerloni, M. (2019) Cortexolone 17α-Propionate (Clascoterone) Is an Androgen Receptor Antagonist in Dermal Papilla Cells in vitro. Journal of Drugs in Dermatology, 18, 197-201.
[16]
Rosette, C., Agan, F.J., Mazzetti, A., Moro, L. and Gerloni, M. (2019) Cortexolone 17α-Propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist That Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes in vitro. Journal of Drugs in Dermatology, 18, 412-418.
[17]
Xing, H., Peng, H., Yang, Y., Lv, K., Zhou, S., Pan, X., et al. (2024) Nitric Oxide Synergizes Minoxidil Delivered by Transdermal Hyaluronic Acid Liposomes for Multimodal Androgenetic-Alopecia Therapy. Bioactive Materials, 32, 190-205. https://doi.org/10.1016/j.bioactmat.2023.09.021
[18]
Jimenez-Cauhe, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Fernandez-Nieto, D., et al. (2019) Effectiveness and Safety of Low-Dose Oral Minoxidil in Male Androgenetic Alopecia. Journal of the American Academy of Dermatology, 81, 648-649. https://doi.org/10.1016/j.jaad.2019.04.054
[19]
Devjani, S., Ezemma, O., Kelley, K.J., Stratton, E. and Senna, M. (2023) Androgenetic Alopecia: Therapy Update. Drugs, 83, 701-715. https://doi.org/10.1007/s40265-023-01880-x
[20]
Tak, Y.J., Lee, S.Y., Cho, A.R. and Kim, Y.S. (2020) A Randomized, Double-Blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia. Stem Cells Translational Medicine, 9, 839-849. https://doi.org/10.1002/sctm.19-0410
[21]
Narita, K., Fukuoka, H., Sekiyama, T., Suga, H. and Harii, K. (2020) Sequential Scalp Assessment in Hair Regeneration Therapy Using an Adipose-Derived Stem Cell-Conditioned Medium. Dermatologic Surgery, 46, 819-825. https://doi.org/10.1097/dss.0000000000002128
[22]
Klein, E.J., Oh, C.S., Karim, M., Shapiro, J. and Lo Sicco, K. (2023) A Practical Approach to the Management of Hair Loss in Patients with Polycystic Ovary Syndrome. Journal of the European Academy of Dermatology and Venereology, 37, 1480-1489. https://doi.org/10.1111/jdv.18842
[23]
Chew, E.G.Y. (2017) Regulatory Pathways Implicated in Male Androgenetic Alopecia Pathogenesis. British Journal of Dermatology, 177, 1159-1160. https://doi.org/10.1111/bjd.15807
[24]
Zhang, L., Xie, J. and Wu, J. (2023) Movement and Androgen Alopecia Correlation Research Progress. Journal of Wuhan University (Medical Edition), 44, 50-52.
[25]
Martinez‐Jacobo, L.A., Ancer‐Arellano, C.I., Villarreal‐ Villarreal, C.D., Ortiz‐Lopez, R., Montufar‐Martinez, M., Trevino, V., et al. (2020) Global Expression Profile and Global Genome Methylation Signatures in Male Patients with Androgenetic Alopecia. Journal of the European Academy of Dermatology and Venereology, 34, e216-e218. https://doi.org/10.1111/jdv.16169
[26]
Li, K., Sun, Y., Liu, S., Zhou, Y., Qu, Q., Wang, G., et al. (2023) The AR/miR-221/IGF-1 Pathway Mediates the Pathogenesis of Androgenetic Alopecia. International Journal of Biological Sciences, 19, 3307-3323. https://doi.org/10.7150/ijbs.80481
[27]
Chen, C., Huang, W., Wang, E.H.C., Tai, K. and Lin, S. (2020) Functional Complexity of Hair Follicle Stem Cell Niche and Therapeutic Targeting of Niche Dysfunction for Hair Regeneration. Journal of Biomedical Science, 27, Article No. 43. https://doi.org/10.1186/s12929-020-0624-8
[28]
Deshmukh, V., Hu, H., Barroga, C., Bossard, C., KC, S., Dellamary, L., et al. (2018) A Small-Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Agent for the Treatment of Osteoarthritis of the Knee. Osteoarthritis and Cartilage, 26, 18-27. https://doi.org/10.1016/j.joca.2017.08.015
